Saturday, 31 October 2026European Markets

AUGROS COSMETICS Stock Went Up By Over 15% In The Last 5 Sessions

Loading stream...

augros cosmetics of france, a company well known for providing customized packaging solutions, has recently experienced a significant surge in its stock market performance. over a period of five trading sessions, they have seen a remarkable 15.56% increase going from eur6.75 to eur7.80 as of last monday. this impressive upturn is in stark contrast to the declining trend in france's cac 40 index which experienced a drop of 1.26% to eur7,340.19.

augros cosmetic overview

as a provider of decorative solutions to perfumers, cosmeticists, and spirits producers, augros cosmetic stands out with its unique offerings in packaging materials, which include glass, plastic and aluminum. the recent and significant growth of the company indicates a potential upturn in the midst of an otherwise underperforming wider market.

financial performance

financially speaking, augros has shown considerable solidity. they boast an earnings per share (eps) figure of eur0.43, and currently, their price to earnings ratio stands at 18.14. this signifies that investors are spending 1814 euros to acquire one share in augros for every euro earned annually by the company.

investor attraction

the shares of augros cosmetics are retaining their attractiveness even in an unstable market. this is largely due to their consistent earnings, as evidenced by impressive earnings per share and an attractive p/e ratio. these indicators suggest that investors are predicting further growth in the future.

investor advice

investors are strongly recommended to keep a close eye on augros cosmetics's stock. it is crucial to monitor both its performance and any strategic moves or announcements made by the company. currently, the company appears to be defying market trends by pushing its shares in the opposite direction.

more news about augros cosmetics (augr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com